News | October 06, 2024
Dr. Reddy’s Laboratories Switzerland incorporates a subsidiary in Denmark
he company will focus on production of any pharmaceutical and biotechnological products
he company will focus on production of any pharmaceutical and biotechnological products
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
New Phase II data show vast majority of patients experiencing no relapses or disability progression
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Subscribe To Our Newsletter & Stay Updated
